文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

利伐沙班用于腹主动脉瘤伴高敏C反应蛋白升高患者(BANBOO):一项随机对照试验的研究方案

Rivaroxaban in patients with abdominal aortic aneurysm and high-sensitivity C-reactive protein elevation (BANBOO): study protocol for a randomized, controlled trial.
PubMed 文献 · Trials · 2023-06-19

BANBOO试验为前瞻性、开放标签、随机对照临床研究,计划从中国北部战区总医院招募60名腹主动脉瘤伴高敏C反应蛋白升高的受试者,按1:1随机分配至利伐沙班组或阿司匹林对照组。主要疗效结局为6个月时血清高敏C反应蛋白水平,次要结局包括影像学检查、主要不良心脑血管事件及其他实验室指标。该试验首次检验利伐沙班对高敏C反应蛋白升高的腹主动脉瘤患者疾病进展的影响。

要点

  • BANBOO试验旨在评估利伐沙班对高敏C反应蛋白升高的腹主动脉瘤患者疾病进展的影响。
  • 研究计划招募60名受试者,按1:1随机分配至利伐沙班组或阿司匹林对照组。
  • 主要疗效结局为6个月时血清高敏C反应蛋白水平。

核心结论

  • BANBOO试验首次检验利伐沙班对高敏C反应蛋白升高的腹主动脉瘤患者疾病进展的影响。

研究设计与样本

  • 前瞻性、开放标签、随机对照临床试验。
  • 计划从中国北部战区总医院招募60名受试者,按1:1随机分配至利伐沙班组或阿司匹林对照组。

主要发现

  • 主要疗效结局为6个月时血清高敏C反应蛋白水平。
  • 次要结局包括影像学检查(腹主动脉瘤最大直径、附壁血栓最大厚度和动脉瘤长度)。
  • 次要结局包括主要不良心脑血管事件(MACCE,含腹主动脉瘤转化、非致死性心肌梗死、急性充血性心力衰竭、支架血栓形成、缺血驱动的靶血管血运重建、血管截肢、卒中、心血管死亡和全因死亡)。
  • 次要结局包括其他实验室检查(肌钙蛋白T、白细胞介素6、D-二聚体和凝血功能)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abdominal aortic aneurysm (AAA) is a fatal disease due to the tendency to rupture. The drug treatment for small AAA without surgical indications has been controversial. Previous studies showed that high-sensitivity C-reactive protein (hs-CRP) had become a potential biomarker of the disease, and the anti-inflammatory effect of rivaroxaban for AAA had been well established. Thus, we hypothesized that rivaroxaban could control the progression of AAA in patients with hs-CRP elevation. METHODS: The study is a prospective, open-label, randomized, controlled clinical trial. Sixty subjects are recruited from the General Hospital of Northern Theatre Command of China. Subjects are randomly assigned (1:1) to the intervention arm (rivaroxaban) or control arm (aspirin). The primary efficacy outcome is the level of serum hs-CRP at 6 months. The secondary outcomes include imaging examination (the maximal diameter of AAA, the maximal thickness of mural thrombus, and the length of aneurysm), major adverse cardiovascular and cerebrovascular events (MACCE, including AAA transformation, non-fatal myocardial infarction, acute congestive heart failure, stent thrombosis, ischemia-driven target vessel revascularization, vascular amputation, stroke, cardiovascular death, and all-cause death), and other laboratory tests (troponin T, interleukin 6, D-dimer, and coagulation function). DISCUSSION: The BANBOO trial tested the effect of rivaroxaban on the progression of AAA in patients with elevated Hs-CRP for the first time. TRIAL REGISTRATION: ChiCTR2100051990, ClinicalTrials.gov, registered on 12 October 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Li J, Ma S, Jia X, et al. Rivaroxaban in patients with abdominal aortic aneurysm and high-sensitivity C-reactive protein elevation (BANBOO): study protocol for a randomized, controlled trial. Trials. 2023. PMID: 37337298. doi:10.1186/s13063-023-07461-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。